Evidence map›Paper›PMID 26829613›Full record

ArticleBiochemistry2016

Characterization of the C-Terminal Nuclease Domain of Herpes Simplex Virus pUL15 as a Target of Nucleotidyltransferase Inhibitors.

Takashi Masaoka, Haiyan Zhao, Danielle R Hirsch, Michael P D'Erasmo, Christine Meck, Brittany Varnado, Ankit Gupta, Marvin J Meyers, Joel Baines, John A Beutler and 3 more

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Takashi MasaokaBasic Research Laboratory, National Cancer Institute , Frederick, Maryland 21702, United States.
Haiyan ZhaoDepartment of Molecular Biosciences, University of Kansas , Lawrence, Kansas 66045, United States.
Danielle R HirschDepartment of Chemistry, Brooklyn College, City University of New York , Brooklyn, New York 11210, United States.
Michael P D'ErasmoDepartment of Chemistry, Brooklyn College, City University of New York , Brooklyn, New York 11210, United States.
Christine MeckDepartment of Chemistry, Brooklyn College, City University of New York , Brooklyn, New York 11210, United States.
Brittany VarnadoDepartment of Molecular Biosciences, University of Kansas , Lawrence, Kansas 66045, United States.
Ankit GuptaDepartment of Molecular Microbiology and Immunology, St. Louis University School of Medicine , St. Louis, Missouri 63104, United States.
Marvin J MeyersDepartment of Chemistry, St. Louis University , St. Louis, Missouri 63103, United States.
Joel BainesSchool of Veterinary Medicine, Louisiana State University , Baton Rouge, Louisiana 70803, United States.
John A BeutlerMolecular Targets Laboratory, National Cancer Institute , Frederick, Maryland 21702, United States.
Ryan P MurelliDepartment of Chemistry, Brooklyn College, City University of New York , Brooklyn, New York 11210, United States.
Liang TangDepartment of Molecular Biosciences, University of Kansas , Lawrence, Kansas 66045, United States.
Stuart F J Le GriceBasic Research Laboratory, National Cancer Institute , Frederick, Maryland 21702, United States.
National Cancer Institute · USUniversity of Kansas · USBrooklyn College · USLouisiana State University · USCity University of New York · USSaint Louis University · USThe Graduate Center, CUNY · US

Funding

Viral and Host Proteins as Therapeutic TargetsZIABC010494 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LE GRICE, STUART F. J. · 2009 to 2021
$9.0M
Development of Natural Product Leads as Anticancer TherapeuticsZIABC011470 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BEUTLER, JOHN · 2012 to 2025
$7.8M
Development and Exploitation of New Synthetic Strategies for TropolonesSC1GM111158 · NIGMS · BROOKLYN COLLEGE · PI MURELLI, RYAN · 2015 to 2023
$3.1M
Genome packaging in DNA virusesR01GM090010 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI TANG, LIANG · 2010 to 2014
$1.3M
Viral and Host Proteins as Therapeutic TargetsZ01BC010494 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LE GRICE, STUART F. J. · 2003 to 2008
$1.0M
Intramural NIH HHS Z01 BC010494NIAID NIH HHS R01AI507421NIGMS NIH HHS R01 GM090010NIGMS NIH HHS R01GM090010NIGMS NIH HHS SC1 GM111158NIGMS NIH HHS SC1GM111158
6 · The paper itself

Abstract

The natural product α-hydroxytropolones manicol and β-thujaplicinol inhibit replication of herpes simplex viruses 1 and 2 (HSV-1 and HSV-2, respectively) at nontoxic concentrations. Because these were originally developed as divalent metal-sequestering inhibitors of the ribonuclease H activity of HIV-1 reverse transcriptase, α-hydroxytropolones likely target related HSV proteins of the nucleotidyltransferase (NTase) superfamily, which share an "RNase H-like" fold. One potential candidate is pUL15, a component of the viral terminase molecular motor complex, whose C-terminal nuclease domain, pUL15C, has recently been crystallized. Crystallography also provided a working model for DNA occupancy of the nuclease active site, suggesting potential protein-nucleic acid contacts over a region of ∼ 14 bp. In this work, we extend crystallographic analysis by examining pUL15C-mediated hydrolysis of short, closely related DNA duplexes. In addition to defining a minimal substrate length, this strategy facilitated construction of a dual-probe fluorescence assay for rapid kinetic analysis of wild-type and mutant nucleases. On the basis of its proposed role in binding the phosphate backbone, studies with pUL15C variant Lys700Ala showed that this mutation affected neither binding of duplex DNA nor binding of small molecule to the active site but caused a 17-fold reduction in the turnover rate (kcat), possibly by slowing conversion of the enzyme-substrate complex to the enzyme-product complex and/or inhibiting dissociation from the hydrolysis product. Finally, with a view of pUL15-associated nuclease activity as an antiviral target, the dual-probe fluorescence assay, in combination with differential scanning fluorimetry, was used to demonstrate inhibition by several classes of small molecules that target divalent metal at the active site.

Indexed as

Enzyme InhibitorsFluorescenceHerpesvirus 1, HumanNucleotidyltransferasesViral ProteinsDNA cleavage and packaging proteins, HerpesvirusEnzyme InhibitorsNucleotidyltransferasesViral Proteins

Identifiers

PMID26829613
PMCPMC4819167
OpenAlexW2235431111

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.